FDA converts Tivdak approval to full approval for cervical cancerNov 9Regulatory decisionPfizertisotumab vedotinUpdated
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Zai Lab reports Q2 2026 results, advances zoci and ZL-1503 toward key milestonesAug 6Quarterly updateZai Lab (Shanghai) Co., Ltd.ZL-1503
Corbus Pharmaceuticals names Leonardo Viana Nicacio as chief medical officerJul 6PeopleCorbus Pharmaceuticals Holdings, Inc.
Pfizer wins five FDA label updates for tofacitinib, ritlecitinib, abrocitinib; Crohn's trial haltedJul 2Weekly roundup, 12 itemsabrocitinibatirmociclib